Survival and Recurrence After ABO-Incompatible Living Donor Liver Transplantation for Hepatocellular Carcinoma

This retrospective cohort study aimed to evaluate long-term oncologic outcomes after ABO-incompatible living donor liver transplantation (LDLT) for hepatocellular carcinoma (HCC). Patients who underwent LDLT between January 2012 and December 2023 at a single tertiary center were included. Outcomes of interest included overall survival and recurrence patterns, with a focus on differences in time to recurrence between ABO-compatible and ABO-incompatible recipients.

Enrolling by Invitation

Interested in participating?

Request Info

Key information

Conditions

Liver Transplantation Adenocarcinoma Carcinoma Carcinoma, Hepatocellular Digestive System Diseases Digestive System Neoplasms Hepatocellular Carcinoma (HCC) Liver Diseases Liver Neoplasms Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Glandular and Epithelial

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

About this study

This study included consecutive adult patients who underwent living donor liver transplantation for hepatocellular carcinoma at the National Cancer Center, Korea. Patients were stratified according to ABO compatibility. The primary outcomes were overall survival and time to recurrence. Survival outcomes were estimated using the Kaplan-Meier method, and risk factors for recurrence were analyzed using Cox proportional hazards regression models. The study aimed to assess whether ABO incompatibility affects long-term survival and recurrence patterns following LDLT.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

• Adult patients (≥18 years)

Underwent living donor liver transplantation for HCC
Transplantation between Jan 2012 - Dec 2023

Exclusion criteria

• Deceased donor liver transplantation

Re-transplantation

Treatment and study plan

Primary outcomes

Overall Survival, Recurrence-free Survival

Time frame: Up to 10 years after transplantation

Time from liver transplantation until death from any cause

Sponsors and collaborators

Lead sponsor

Seoung Hoon Kim

Other Gov

Registry information

Acronym: HCC

Important dates

Study start: 2012
Primary completion: 2025
Study completion: 2026
First posted: Jul 14, 2026
Registry last updated: Jul 14, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed